FAK Splicing Variants SCLC Diagnosis Target
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for small-cell lung cancer (SCLC) lack effective markers and targets, leading to poor prognosis and limited treatment options, with splicing variants of focal adhesion kinase (FAK) remaining unexplored despite their potential significance.
Innovation Solution
Identification and utilization of FAK splicing variants, such as FAK6.7, FAK6, and FAK7, as markers for clinical diagnosis and targets for drug therapy, using reagents and inhibitors like PF-562271 to inhibit FAK kinase activity, potentially combined with immunotherapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional diagnostic and therapeutic approaches are used for SCLC, then treatment can be provided, but effective markers and targets are lacking leading to poor prognosis
Solution Approach 1:
The patent performs preliminary identification and characterization of FAK splicing variants (FAK6.7, FAK6, FAK7) before clinical application. By pre-establishing these variants as diagnostic markers and therapeutic targets through sequencing and functional studies, the invention prepares actionable information that can be directly applied to improve SCLC prognosis without requiring de novo discovery at the point of care.
Solution Approach 2:
The patent introduces FAK splicing variants as intermediary biomarkers that bridge the gap between conventional diagnostic approaches and effective treatment. These variants serve as mediators that provide actionable information for both diagnosis and targeted therapy, connecting the lack of effective markers to improved prognostic capability through a discoverable molecular pathway.
2Measurement precision
If FAK splicing variants are used as diagnostic markers, then detection precision is improved, but the complexity of detection increases
Solution Approach 1:
The patent extracts specific FAK splicing variant sequences (FAK6.7, FAK6, FAK7) from the complex FAK gene structure to create targeted detection markers. By isolating and characterizing these specific variants, the invention enables focused detection approaches that achieve high precision without requiring analysis of the entire FAK gene or other unrelated genomic regions, thereby reducing detection complexity while maintaining accuracy.
3Productivity
If FAK-targeting drugs are used to inhibit kinase activity, then cell proliferation is suppressed, but the complexity of treatment regimens increases
Solution Approach 1:
The patent converts the abnormal high expression and activity of FAK splicing variants, which drive SCLC cell proliferation and poor prognosis, into beneficial therapeutic targets. By identifying these variants as drivers of tumor growth, the invention enables the use of FAK inhibitors to suppress proliferation, turning the harmful overactivity of FAK into a vulnerability that can be exploited for cancer treatment.
Data Source
AI summary
The present disclosure provides focal adhesion kinase (FAK) splicing variants and use thereof, specifically, the use of reagents for detecting FAK splicing variants in the manufacture of diagnostic agents for diagnosis of small cell lung cancer (SCLC), and also the use of FAK splicing variants as a target in the screening and/or manufacture of a medicament for treatment of SCLC. The FAK splicing variants can be used as clinical diagnostic markers of SCLC, and are promising in clinical applications of FAK kinase inhibitors.